-
1
-
-
84859341109
-
Dipeptidyl peptidase-4 inhibitors: 3 years of experience
-
G. Derosa, and P. Maffioli Dipeptidyl peptidase-4 inhibitors: 3 years of experience Diabetes Technol Ther 14 4 2012 350 364
-
(2012)
Diabetes Technol Ther
, vol.14
, Issue.4
, pp. 350-364
-
-
Derosa, G.1
Maffioli, P.2
-
2
-
-
84869798707
-
A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function
-
G. Derosa, A. Carbone, and A. D'Angelo et al. A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function Expert Opin Pharmacother 13 17 2012 2433 2442
-
(2012)
Expert Opin Pharmacother
, vol.13
, Issue.17
, pp. 2433-2442
-
-
Derosa, G.1
Carbone, A.2
D'Angelo, A.3
-
3
-
-
84879592855
-
A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and β-cell function: The triple oral therapy
-
G. Derosa, A.F. Cicero, and I.G. Franzetti et al. A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and β-cell function: the triple oral therapy Diabet Med 30 7 2013 846 854
-
(2013)
Diabet Med
, vol.30
, Issue.7
, pp. 846-854
-
-
Derosa, G.1
Cicero, A.F.2
Franzetti, I.G.3
-
4
-
-
77952316298
-
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients
-
G. Derosa, P. Maffioli, and S.A. Salvadeo et al. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients Metabolism 59 6 2010 887 895
-
(2010)
Metabolism
, vol.59
, Issue.6
, pp. 887-895
-
-
Derosa, G.1
Maffioli, P.2
Salvadeo, S.A.3
-
5
-
-
84878380125
-
Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients
-
G. Derosa, P.D. Ragonesi, and A. Carbone et al. Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients Pharmacol Res 73 2013 20 26
-
(2013)
Pharmacol Res
, vol.73
, pp. 20-26
-
-
Derosa, G.1
Ragonesi, P.D.2
Carbone, A.3
-
6
-
-
84870201257
-
Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: A 12-month, placebo-controlled study
-
G. Derosa, P.D. Ragonesi, and A. Carbone et al. Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study Expert Opin Pharmacother 13 18 2012 2581 2591
-
(2012)
Expert Opin Pharmacother
, vol.13
, Issue.18
, pp. 2581-2591
-
-
Derosa, G.1
Ragonesi, P.D.2
Carbone, A.3
-
7
-
-
84861982613
-
Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients
-
G. Derosa, P.D. Ragonesi, and A. Carbone et al. Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients Diabetes Technol Ther 14 6 2012 475 484
-
(2012)
Diabetes Technol Ther
, vol.14
, Issue.6
, pp. 475-484
-
-
Derosa, G.1
Ragonesi, P.D.2
Carbone, A.3
-
8
-
-
77955020170
-
Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients
-
G. Derosa, P. Maffioli, and I. Ferrari et al. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients Horm Metab Res 42 9 2010 663 669
-
(2010)
Horm Metab Res
, vol.42
, Issue.9
, pp. 663-669
-
-
Derosa, G.1
Maffioli, P.2
Ferrari, I.3
-
9
-
-
34347393269
-
Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus
-
Y.L. He, D. Serra, and Y. Wang et al. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus Clin Pharmacokinet 46 7 2007 577 588
-
(2007)
Clin Pharmacokinet
, vol.46
, Issue.7
, pp. 577-588
-
-
He, Y.L.1
Serra, D.2
Wang, Y.3
-
10
-
-
2442482515
-
Inhibition of dipeptidylpeptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes
-
B. Ahren, M. Landin-Olsson, and P.-A. Jansson et al. Inhibition of dipeptidylpeptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes J Clin Endocrinol Metab 89 2004 2078 2084
-
(2004)
J Clin Endocrinol Metab
, vol.89
, pp. 2078-2084
-
-
Ahren, B.1
Landin-Olsson, M.2
Jansson, P.-A.3
-
11
-
-
77954250537
-
The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action
-
K.J. Hare, T. Vilsboll, and M. Asmar et al. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action Diabetes 59 2010 1765 1770
-
(2010)
Diabetes
, vol.59
, pp. 1765-1770
-
-
Hare, K.J.1
Vilsboll, T.2
Asmar, M.3
-
12
-
-
34147189738
-
The dipeptidylpeptidase-4 inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients
-
B. Balas, M.R. Baig, and C. Watson et al. The dipeptidylpeptidase-4 inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients J Clin Endocrinol Metab 92 2007 1249 1255
-
(2007)
J Clin Endocrinol Metab
, vol.92
, pp. 1249-1255
-
-
Balas, B.1
Baig, M.R.2
Watson, C.3
-
13
-
-
58149465731
-
Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice
-
H. Duez, A.C. Smith, and C. Xiao et al. Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice Endocrinology 150 1 2009 56 62
-
(2009)
Endocrinology
, vol.150
, Issue.1
, pp. 56-62
-
-
Duez, H.1
Smith, A.C.2
Xiao, C.3
-
14
-
-
84864802728
-
Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes
-
E. Muscelli, A. Casolaro, and A. Gastaldelli et al. Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes J Clin Endocrinol Metab 97 8 2012 2818 2826
-
(2012)
J Clin Endocrinol Metab
, vol.97
, Issue.8
, pp. 2818-2826
-
-
Muscelli, E.1
Casolaro, A.2
Gastaldelli, A.3
-
15
-
-
39049141231
-
Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes
-
K. Azuma, Z. Rádiková, and J. Mancino et al. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes J Clin Endocrinol Metab 93 2008 459 464
-
(2008)
J Clin Endocrinol Metab
, vol.93
, pp. 459-464
-
-
Azuma, K.1
Rádiková, Z.2
Mancino, J.3
-
16
-
-
62349138180
-
Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients
-
M. Boschmann, S. Engeli, and K. Dobberstein et al. Dipeptidyl-peptidase- IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients J Clin Endocrinol Metab 94 2009 846 852
-
(2009)
J Clin Endocrinol Metab
, vol.94
, pp. 846-852
-
-
Boschmann, M.1
Engeli, S.2
Dobberstein, K.3
-
17
-
-
0035511643
-
Recent findings in the study of postprandial lipemia
-
E.J. Parks Recent findings in the study of postprandial lipemia Curr Atheroscler Rep 3 6 2001 462 470
-
(2001)
Curr Atheroscler Rep
, vol.3
, Issue.6
, pp. 462-470
-
-
Parks, E.J.1
-
18
-
-
84870294666
-
Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: Evaluation with euglycemic clamp an oral fat load
-
G. Derosa, A.F. Cicero, and E. Fogari et al. Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp an oral fat load J Clin Lipidol 6 6 2012 553 564
-
(2012)
J Clin Lipidol
, vol.6
, Issue.6
, pp. 553-564
-
-
Derosa, G.1
Cicero, A.F.2
Fogari, E.3
-
19
-
-
80051703255
-
Effects of n-3 PUFAs on insulin resistance after an oral fat load
-
G. Derosa, A.F.G. Cicero, and E. Fogari et al. Effects of n-3 PUFAs on insulin resistance after an oral fat load Eur J Lipid Sci Technol 113 8 2011 950 960
-
(2011)
Eur J Lipid Sci Technol
, vol.113
, Issue.8
, pp. 950-960
-
-
Derosa, G.1
Cicero, A.F.G.2
Fogari, E.3
-
20
-
-
79958861430
-
Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load
-
G. Derosa, A.F. Cicero, and E. Fogari et al. Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load Horm Metab Res 43 7 2011 505 512
-
(2011)
Horm Metab Res
, vol.43
, Issue.7
, pp. 505-512
-
-
Derosa, G.1
Cicero, A.F.2
Fogari, E.3
-
21
-
-
79959997617
-
Acarbose on insulin resistance after an oral fat load: A double-blind, placebo controlled study
-
G. Derosa, P. Maffioli, and A. D'Angelo et al. Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study J Diabetes Complications 25 4 2011 258 266
-
(2011)
J Diabetes Complications
, vol.25
, Issue.4
, pp. 258-266
-
-
Derosa, G.1
Maffioli, P.2
D'Angelo, A.3
-
22
-
-
78650679019
-
Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load
-
G. Derosa, P. Maffioli, and I. Ferrari et al. Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load Eur J Pharmacol 651 1-3 2011 240 250
-
(2011)
Eur J Pharmacol
, vol.651
, Issue.13
, pp. 240-250
-
-
Derosa, G.1
Maffioli, P.2
Ferrari, I.3
-
23
-
-
66149148712
-
Oral fat load effects on inflammation and endothelial stress markers in healthy subjects
-
G. Derosa, I. Ferrari, and A. D'Angelo et al. Oral fat load effects on inflammation and endothelial stress markers in healthy subjects Heart Vessels 24 3 2009 204 210
-
(2009)
Heart Vessels
, vol.24
, Issue.3
, pp. 204-210
-
-
Derosa, G.1
Ferrari, I.2
D'Angelo, A.3
-
24
-
-
77749246297
-
Candesartan effect on inflammation in hypertension
-
G. Derosa, P. Maffioli, and S.A. Salvadeo et al. Candesartan effect on inflammation in hypertension Hypertens Res 33 3 2010 209 213
-
(2010)
Hypertens Res
, vol.33
, Issue.3
, pp. 209-213
-
-
Derosa, G.1
Maffioli, P.2
Salvadeo, S.A.3
-
25
-
-
77953536451
-
Effects of a standardized oral fat load on vascular remodelling markers in healthy subjects
-
G. Derosa, I. Ferrari, and A. D'Angelo et al. Effects of a standardized oral fat load on vascular remodelling markers in healthy subjects Microvasc Res 80 1 2010 110 115
-
(2010)
Microvasc Res
, vol.80
, Issue.1
, pp. 110-115
-
-
Derosa, G.1
Ferrari, I.2
D'Angelo, A.3
-
26
-
-
33846414720
-
Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
-
L. Rydén, E. Standl, and M. Bartnik et al. Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur Heart J 28 1 2007 88 136
-
(2007)
Eur Heart J
, vol.28
, Issue.1
, pp. 88-136
-
-
Rydén, L.1
Standl, E.2
Bartnik, M.3
-
27
-
-
33749065167
-
Summary of American Heart Association diet and lifestyle recommendations revision 2006
-
A.H. Lichtenstein, L.J. Appel, and M. Brands et al. Summary of American Heart Association diet and lifestyle recommendations revision 2006 Arterioscler Thromb Vasc Biol 26 2006 2186 2191
-
(2006)
Arterioscler Thromb Vasc Biol
, vol.26
, pp. 2186-2191
-
-
Lichtenstein, A.H.1
Appel, L.J.2
Brands, M.3
-
28
-
-
0017835519
-
The glycosylation of haemoglobin. Relevance to diabetes mellitus
-
H.F. Bunn, K.H. Gabbay, and P.M. Gallop The glycosylation of haemoglobin. Relevance to diabetes mellitus Science 200 1978 21 27
-
(1978)
Science
, vol.200
, pp. 21-27
-
-
Bunn, H.F.1
Gabbay, K.H.2
Gallop, P.M.3
-
29
-
-
0032887833
-
A desktop guide to type 2 diabetes mellitus
-
European Diabetes Policy Group
-
European Diabetes Policy Group A desktop guide to type 2 diabetes mellitus Diabet Med 16 1999 716 730
-
(1999)
Diabet Med
, vol.16
, pp. 716-730
-
-
-
30
-
-
0015376786
-
Determination of total serum insulin (IRI) in insulin-treated diabetic patients
-
L.G. Heding Determination of total serum insulin (IRI) in insulin-treated diabetic patients Diabetologia 8 1972 260 266
-
(1972)
Diabetologia
, vol.8
, pp. 260-266
-
-
Heding, L.G.1
-
31
-
-
0021813187
-
Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man
-
D.R. Matthews, J.P. Hosker, and A.S. Rudenski et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412 419
-
(1985)
Diabetologia
, vol.28
, pp. 412-419
-
-
Matthews, D.R.1
Hosker, J.P.2
Rudenski, A.S.3
-
33
-
-
0017358973
-
Enzymatische Bestimmung des Gesamtcholesterins mit dem Greiner Selective Analyzer (GSA II)
-
S. Klose, and K. Borner Enzymatische Bestimmung des Gesamtcholesterins mit dem Greiner Selective Analyzer (GSA II) J Clin Chem Clin Biochem 15 1978 121 130
-
(1978)
J Clin Chem Clin Biochem
, vol.15
, pp. 121-130
-
-
Klose, S.1
Borner, K.2
-
35
-
-
33745026603
-
The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum
-
R.J. Havel, H.A. Edr, and J.H. Bragdon The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum J Clin Invest 34 1955 1345 1353
-
(1955)
J Clin Invest
, vol.34
, pp. 1345-1353
-
-
Havel, R.J.1
Edr, H.A.2
Bragdon, J.H.3
-
36
-
-
0015348189
-
Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge
-
W.T. Friedewald, R.I. Levy, and D.S. Fredrickson Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
-
(1972)
Clin Chem
, vol.18
, pp. 499-502
-
-
Friedewald, W.T.1
Levy, R.I.2
Fredrickson, D.S.3
-
37
-
-
0031833298
-
First direct assay for intact human proinsulin
-
P. Houssa, B. Dinensen, and M. Deberg et al. First direct assay for intact human proinsulin Clin Chem 44 7 1998 1514 1519
-
(1998)
Clin Chem
, vol.44
, Issue.7
, pp. 1514-1519
-
-
Houssa, P.1
Dinensen, B.2
Deberg, M.3
-
38
-
-
0020456354
-
Evidence that peak II GLI or enteroglucagon is identical to the C-terminal sequence (residues 33-69) of glicentin
-
J.J. Holst Evidence that peak II GLI or enteroglucagon is identical to the C-terminal sequence (residues 33-69) of glicentin Biochem J 207 1982 381 388
-
(1982)
Biochem J
, vol.207
, pp. 381-388
-
-
Holst, J.J.1
-
39
-
-
0038359739
-
Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans
-
M. Yannakoulia, N. Yiannakouris, and S. Blüher et al. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans J Clin Endocrinol Metab 88 4 2003 1730 1736
-
(2003)
J Clin Endocrinol Metab
, vol.88
, Issue.4
, pp. 1730-1736
-
-
Yannakoulia, M.1
Yiannakouris, N.2
Blüher, S.3
-
40
-
-
34447118227
-
Retinol binding protein-4 levels and clinical features of type 2 diabetes patients
-
K. Takebayashi, M. Suetsugu, and S. Wakabayashi et al. Retinol binding protein-4 levels and clinical features of type 2 diabetes patients J Clin Endocrinol Metab 92 7 2007 2712 2719
-
(2007)
J Clin Endocrinol Metab
, vol.92
, Issue.7
, pp. 2712-2719
-
-
Takebayashi, K.1
Suetsugu, M.2
Wakabayashi, S.3
-
41
-
-
23044473651
-
Visceral adipose tissue-derived serine protease inhibitor: A unique insulin-sensitizing adipocytokine in obesity
-
K. Hida, J. Wada, and J. Eguchi et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity Proc Natl Acad Sci U S A 102 2005 10610 10615
-
(2005)
Proc Natl Acad Sci U S A
, vol.102
, pp. 10610-10615
-
-
Hida, K.1
Wada, J.2
Eguchi, J.3
-
42
-
-
36849020047
-
Molecular characteristics of serum visfatin and differential detection by immunoassays
-
A. Korner, A. Garten, and M. Bluher et al. Molecular characteristics of serum visfatin and differential detection by immunoassays J Clin Endocrinol Metab 92 2007 4783 4791
-
(2007)
J Clin Endocrinol Metab
, vol.92
, pp. 4783-4791
-
-
Korner, A.1
Garten, A.2
Bluher, M.3
-
43
-
-
0018520840
-
Glucose clamp technique, a method for quantifying insulin secretion and resistance
-
R.A. De Fronzo, J.A. Tobin, and B. Andres Glucose clamp technique, a method for quantifying insulin secretion and resistance Am J Physiol 237 1979 214 223
-
(1979)
Am J Physiol
, vol.237
, pp. 214-223
-
-
De Fronzo, R.A.1
Tobin, J.A.2
Andres, B.3
-
44
-
-
0023191508
-
Insulin resistance in essential hypertension
-
E. Ferrannini, G. Buzzigoli, and R. Bonadonna et al. Insulin resistance in essential hypertension N Engl J Med 317 6 1987 350 357
-
(1987)
N Engl J Med
, vol.317
, Issue.6
, pp. 350-357
-
-
Ferrannini, E.1
Buzzigoli, G.2
Bonadonna, R.3
-
46
-
-
84861406329
-
Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients
-
H.J. Jeon, and T.K. Oh Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients Diabetes Metab J 35 5 2011 529 535
-
(2011)
Diabetes Metab J
, vol.35
, Issue.5
, pp. 529-535
-
-
Jeon, H.J.1
Oh, T.K.2
-
47
-
-
84876785125
-
Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency
-
J.C. Arjona Ferreira, M. Marre, and N. Barzilai et al. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency Diabetes Care 36 5 2013 1067 1073
-
(2013)
Diabetes Care
, vol.36
, Issue.5
, pp. 1067-1073
-
-
Arjona Ferreira, J.C.1
Marre, M.2
Barzilai, N.3
-
48
-
-
84887204684
-
Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring
-
Y.L. He, G. Foteinos, and S. Neelakantham et al. Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring Diabetes Obes Metab 15 12 2013 1111 1119
-
(2013)
Diabetes Obes Metab
, vol.15
, Issue.12
, pp. 1111-1119
-
-
He, Y.L.1
Foteinos, G.2
Neelakantham, S.3
-
49
-
-
0036615275
-
The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes
-
R.N. Bergman, D.T. Finegood, and S.E. Kahn The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes Eur J Clin Invest 32 3 2002 35 45
-
(2002)
Eur J Clin Invest
, vol.32
, Issue.3
, pp. 35-45
-
-
Bergman, R.N.1
Finegood, D.T.2
Kahn, S.E.3
-
50
-
-
65549109984
-
Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus
-
J. Rosenstock, M. Niggli, and M. Maldonado-Lutomirsky Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus Diabetes Obes Metab 11 6 2009 571 578
-
(2009)
Diabetes Obes Metab
, vol.11
, Issue.6
, pp. 571-578
-
-
Rosenstock, J.1
Niggli, M.2
Maldonado-Lutomirsky, M.3
-
51
-
-
84895529499
-
Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: A 2-year study evaluation
-
G. Derosa, P.D. Ragonesi, and E. Fogari et al. Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation Fundam Clin Pharmacol 28 2 2014 221 229
-
(2014)
Fundam Clin Pharmacol
, vol.28
, Issue.2
, pp. 221-229
-
-
Derosa, G.1
Ragonesi, P.D.2
Fogari, E.3
-
52
-
-
33746690405
-
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes
-
N. Matikainen, S. Mänttäri, and A. Schweizer et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes Diabetologia 49 9 2006 2049 2057
-
(2006)
Diabetologia
, vol.49
, Issue.9
, pp. 2049-2057
-
-
Matikainen, N.1
Mänttäri, S.2
Schweizer, A.3
-
53
-
-
23844463766
-
Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes
-
A. Mari, W.M. Sallas, and Y.L. He et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes J Clin Endocrinol Metab 90 8 2005 4888 4894
-
(2005)
J Clin Endocrinol Metab
, vol.90
, Issue.8
, pp. 4888-4894
-
-
Mari, A.1
Sallas, W.M.2
He, Y.L.3
|